Codexis Shares Slide On CEO Transition

Codexis Shares Slide On CEO Transition
  • Codexis, Inc. CDXS has appointed Dr. Stephen Dilly, Board member, and biotechnology veteran, as President and CEO, effective August 9, 2022.
  • After ten years of leading the transformation and growth of Codexis, the current President and CEO, John Nicols, will step down for personal reasons.
  • Mr. Nicols will remain on Codexis' Board through the annual meeting in June 2023 and will assume a new multi-year role as Strategic Advisor to provide ongoing support to the company.
  • Most recently, Dr. Stephen Dilly served as President and CEO of Sierra Oncology through its recent sale to GlaxoSmithKline GSK for $1.9 billion. 
  • Previously, he served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2.6 billion. He holds an MBBS and a Ph.D. in Cardiac Physiology from the University of London.
  • Recently, 
  • Last week, Codexis released the preliminary revenue expectations for Q2, which were lower than the prior guidance.
  • Price Action: CDXS shares are trading lower by 2.79% at $6.62 during the post-market session on Monday.

Posted In: Briefswhy it's movingNewsSmall CapMoversTrading Ideas